Introduction: In recent years, the number of adult patients with severe AD, resistant to standard therapy is growing. Dupilumab was the first biotic drug approved for the treatment of severe AD. The purpose of the work – evaluation of the effectiveness of dupilumab with severe AD.

Material and methods: The efficacy of dupilumab was evaluated in 3 patients, 1 woman and 2 men. The age -30 to 57 years. Everyone has a disease start from infancy. Patients have a severe atopic profile with multiple hypersensivety to the food and airborne allergens, to enterotoxins Staphylococcus aureus and Candida albicans, blood eosinophilia and very high total IgE levels. The hyperergic response of the immune system to a wide range of allergens has led to the extreme overproduction of IgE. Patients have often received therapy with glucocorticosteroids, cytostatics and topic calcineurin inhibitor. Thus, therapy with dupilumab was the only possible way to control severe AD in these patients at the present stage. The analysis of the effectiveness of therapy is assessed by the SCORAD, IGA scales.

Clinical results: All patients take dupilumab at a starting dose -600 mg and after -300 mg once every 4 weeks. The first positive results from dupilumab were obtained after the third injection of the drug, with relief of inflammatory signs on skin with improvement in the quality of life.

Conclusions: The results of the first treatment in Kazakhstan with dupilumab of severe AD allow recommending dupilumab to patients who are refractory to standard therapy.

Annotation: The first experience in the use of biological therapy with dupilumab for severe atopic dermatitis (AD) in Kazakhstan.

Summary: The results of the first treatment in Kazakhstan with dupilumab of severe AD allow recommending dupilumab to patients who are refractory to standard therapy.

Key words: Atopic dermatitis, Dupilumab.